Global Antibody Drug Conjugates (ADCs) Market 2022 by Company, Regions, Type and Application, Forecast to 2028
The Antibody Drug Conjugates (ADCs) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Antibody Drug Conjugates (ADCs) market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Antibody Drug Conjugates (ADCs) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Seattle Genetics Technology segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Antibody Drug Conjugates (ADCs) include Roche, Pfizer, Novartis, Genmab, and Bayer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Antibody Drug Conjugates (ADCs) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Seattle Genetics Technology
ImmunoGen Technology
Immunomedics Technology
Market segment by Application, can be divided into
Hospital
Clinics
Others
Market segment by players, this report covers
Roche
Pfizer
Novartis
Genmab
Bayer
Seattle Genetics
Takeda Pharmaceuticals
AbbVie
AbGenomics
ADC Therapeutics
Astellas Pharma
Kairos Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Antibody Drug Conjugates (ADCs) product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Antibody Drug Conjugates (ADCs), with revenue, gross margin and global market share of Antibody Drug Conjugates (ADCs) from 2019 to 2022.
Chapter 3, the Antibody Drug Conjugates (ADCs) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Antibody Drug Conjugates (ADCs) market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Antibody Drug Conjugates (ADCs) research findings and conclusion, appendix and data source.
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of Antibody Drug Conjugates (ADCs)
1.2 Classification of Antibody Drug Conjugates (ADCs) by Type
1.2.1 Overview: Global Antibody Drug Conjugates (ADCs) Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type in 2021
1.2.3 Seattle Genetics Technology
1.2.4 ImmunoGen Technology
1.2.5 Immunomedics Technology
1.3 Global Antibody Drug Conjugates (ADCs) Market by Application
1.3.1 Overview: Global Antibody Drug Conjugates (ADCs) Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Global Antibody Drug Conjugates (ADCs) Market Size & Forecast
1.5 Global Antibody Drug Conjugates (ADCs) Market Size and Forecast by Region
1.5.1 Global Antibody Drug Conjugates (ADCs) Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Antibody Drug Conjugates (ADCs) Market Size by Region, (2017-2022)
1.5.3 North America Antibody Drug Conjugates (ADCs) Market Size and Prospect (2017-2028)
1.5.4 Europe Antibody Drug Conjugates (ADCs) Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size and Prospect (2017-2028)
1.5.6 South America Antibody Drug Conjugates (ADCs) Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Antibody Drug Conjugates (ADCs) Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Antibody Drug Conjugates (ADCs) Market Drivers
1.6.2 Antibody Drug Conjugates (ADCs) Market Restraints
1.6.3 Antibody Drug Conjugates (ADCs) Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Antibody Drug Conjugates (ADCs) Product and Solutions
2.1.4 Roche Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Roche Recent Developments and Future Plans
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Antibody Drug Conjugates (ADCs) Product and Solutions
2.2.4 Pfizer Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Pfizer Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Antibody Drug Conjugates (ADCs) Product and Solutions
2.3.4 Novartis Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Novartis Recent Developments and Future Plans
2.4 Genmab
2.4.1 Genmab Details
2.4.2 Genmab Major Business
2.4.3 Genmab Antibody Drug Conjugates (ADCs) Product and Solutions
2.4.4 Genmab Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Genmab Recent Developments and Future Plans
2.5 Bayer
2.5.1 Bayer Details
2.5.2 Bayer Major Business
2.5.3 Bayer Antibody Drug Conjugates (ADCs) Product and Solutions
2.5.4 Bayer Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Bayer Recent Developments and Future Plans
2.6 Seattle Genetics
2.6.1 Seattle Genetics Details
2.6.2 Seattle Genetics Major Business
2.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Product and Solutions
2.6.4 Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Seattle Genetics Recent Developments and Future Plans
2.7 Takeda Pharmaceuticals
2.7.1 Takeda Pharmaceuticals Details
2.7.2 Takeda Pharmaceuticals Major Business
2.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product and Solutions
2.7.4 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Takeda Pharmaceuticals Recent Developments and Future Plans
2.8 AbbVie
2.8.1 AbbVie Details
2.8.2 AbbVie Major Business
2.8.3 AbbVie Antibody Drug Conjugates (ADCs) Product and Solutions
2.8.4 AbbVie Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 AbbVie Recent Developments and Future Plans
2.9 AbGenomics
2.9.1 AbGenomics Details
2.9.2 AbGenomics Major Business
2.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Product and Solutions
2.9.4 AbGenomics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 AbGenomics Recent Developments and Future Plans
2.10 ADC Therapeutics
2.10.1 ADC Therapeutics Details
2.10.2 ADC Therapeutics Major Business
2.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions
2.10.4 ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 ADC Therapeutics Recent Developments and Future Plans
2.11 Astellas Pharma
2.11.1 Astellas Pharma Details
2.11.2 Astellas Pharma Major Business
2.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Product and Solutions
2.11.4 Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Astellas Pharma Recent Developments and Future Plans
2.12 Kairos Therapeutics
2.12.1 Kairos Therapeutics Details
2.12.2 Kairos Therapeutics Major Business
2.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions
2.12.4 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Kairos Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Antibody Drug Conjugates (ADCs) Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Antibody Drug Conjugates (ADCs) Players Market Share in 2021
3.2.2 Top 10 Antibody Drug Conjugates (ADCs) Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Antibody Drug Conjugates (ADCs) Players Head Office, Products and Services Provided
3.4 Antibody Drug Conjugates (ADCs) Mergers & Acquisitions
3.5 Antibody Drug Conjugates (ADCs) New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Antibody Drug Conjugates (ADCs) Revenue and Market Share by Type (2017-2022)
4.2 Global Antibody Drug Conjugates (ADCs) Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Application (2017-2022)
5.2 Global Antibody Drug Conjugates (ADCs) Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2028)
6.2 North America Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2028)
6.3 North America Antibody Drug Conjugates (ADCs) Market Size by Country
6.3.1 North America Antibody Drug Conjugates (ADCs) Revenue by Country (2017-2028)
6.3.2 United States Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
6.3.3 Canada Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
6.3.4 Mexico Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2028)
7.2 Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2028)
7.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Country
7.3.1 Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2017-2028)
7.3.2 Germany Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
7.3.3 France Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
7.3.5 Russia Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
7.3.6 Italy Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2028)
8.2 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2028)
8.3 Asia-Pacific Antibody Drug Conjugates (ADCs) Market Size by Region
8.3.1 Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Region (2017-2028)
8.3.2 China Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
8.3.3 Japan Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
8.3.4 South Korea Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
8.3.5 India Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
8.3.7 Australia Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2028)
9.2 South America Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2028)
9.3 South America Antibody Drug Conjugates (ADCs) Market Size by Country
9.3.1 South America Antibody Drug Conjugates (ADCs) Revenue by Country (2017-2028)
9.3.2 Brazil Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
9.3.3 Argentina Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2028)
10.2 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2028)
10.3 Middle East & Africa Antibody Drug Conjugates (ADCs) Market Size by Country
10.3.1 Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Country (2017-2028)
10.3.2 Turkey Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
10.3.4 UAE Antibody Drug Conjugates (ADCs) Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Antibody Drug Conjugates (ADCs) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Antibody Drug Conjugates (ADCs) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Antibody Drug Conjugates (ADCs) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) by Region (2017-2022)
Table 5. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Region (2023-2028)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Antibody Drug Conjugates (ADCs) Product and Solutions
Table 9. Roche Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Pfizer Corporate Information, Head Office, and Major Competitors
Table 11. Pfizer Major Business
Table 12. Pfizer Antibody Drug Conjugates (ADCs) Product and Solutions
Table 13. Pfizer Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Novartis Corporate Information, Head Office, and Major Competitors
Table 15. Novartis Major Business
Table 16. Novartis Antibody Drug Conjugates (ADCs) Product and Solutions
Table 17. Novartis Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Genmab Corporate Information, Head Office, and Major Competitors
Table 19. Genmab Major Business
Table 20. Genmab Antibody Drug Conjugates (ADCs) Product and Solutions
Table 21. Genmab Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Bayer Corporate Information, Head Office, and Major Competitors
Table 23. Bayer Major Business
Table 24. Bayer Antibody Drug Conjugates (ADCs) Product and Solutions
Table 25. Bayer Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Seattle Genetics Corporate Information, Head Office, and Major Competitors
Table 27. Seattle Genetics Major Business
Table 28. Seattle Genetics Antibody Drug Conjugates (ADCs) Product and Solutions
Table 29. Seattle Genetics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Takeda Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 31. Takeda Pharmaceuticals Major Business
Table 32. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Product and Solutions
Table 33. Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. AbbVie Corporate Information, Head Office, and Major Competitors
Table 35. AbbVie Major Business
Table 36. AbbVie Antibody Drug Conjugates (ADCs) Product and Solutions
Table 37. AbbVie Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. AbGenomics Corporate Information, Head Office, and Major Competitors
Table 39. AbGenomics Major Business
Table 40. AbGenomics Antibody Drug Conjugates (ADCs) Product and Solutions
Table 41. AbGenomics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. ADC Therapeutics Corporate Information, Head Office, and Major Competitors
Table 43. ADC Therapeutics Major Business
Table 44. ADC Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions
Table 45. ADC Therapeutics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Astellas Pharma Corporate Information, Head Office, and Major Competitors
Table 47. Astellas Pharma Major Business
Table 48. Astellas Pharma Antibody Drug Conjugates (ADCs) Product and Solutions
Table 49. Astellas Pharma Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Kairos Therapeutics Corporate Information, Head Office, and Major Competitors
Table 51. Kairos Therapeutics Major Business
Table 52. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Product and Solutions
Table 53. Kairos Therapeutics Antibody Drug Conjugates (ADCs) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 55. Global Antibody Drug Conjugates (ADCs) Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 56. Breakdown of Antibody Drug Conjugates (ADCs) by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Antibody Drug Conjugates (ADCs) Players Head Office, Products and Services Provided
Table 58. Antibody Drug Conjugates (ADCs) Mergers & Acquisitions in the Past Five Years
Table 59. Antibody Drug Conjugates (ADCs) New Entrants and Expansion Plans
Table 60. Global Antibody Drug Conjugates (ADCs) Revenue (USD Million) by Type (2017-2022)
Table 61. Global Antibody Drug Conjugates (ADCs) Revenue Share by Type (2017-2022)
Table 62. Global Antibody Drug Conjugates (ADCs) Revenue Forecast by Type (2023-2028)
Table 63. Global Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2022)
Table 64. Global Antibody Drug Conjugates (ADCs) Revenue Forecast by Application (2023-2028)
Table 65. North America Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2022) & (USD Million)
Table 66. North America Antibody Drug Conjugates (ADCs) Revenue by Type (2023-2028) & (USD Million)
Table 67. North America Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2022) & (USD Million)
Table 68. North America Antibody Drug Conjugates (ADCs) Revenue by Application (2023-2028) & (USD Million)
Table 69. North America Antibody Drug Conjugates (ADCs) Revenue by Country (2017-2022) & (USD Million)
Table 70. North America Antibody Drug Conjugates (ADCs) Revenue by Country (2023-2028) & (USD Million)
Table 71. Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2022) & (USD Million)
Table 72. Europe Antibody Drug Conjugates (ADCs) Revenue by Type (2023-2028) & (USD Million)
Table 73. Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2022) & (USD Million)
Table 74. Europe Antibody Drug Conjugates (ADCs) Revenue by Application (2023-2028) & (USD Million)
Table 75. Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2017-2022) & (USD Million)
Table 76. Europe Antibody Drug Conjugates (ADCs) Revenue by Country (2023-2028) & (USD Million)
Table 77. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2022) & (USD Million)
Table 78. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Type (2023-2028) & (USD Million)
Table 79. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2022) & (USD Million)
Table 80. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Application (2023-2028) & (USD Million)
Table 81. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Region (2017-2022) & (USD Million)
Table 82. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue by Region (2023-2028) & (USD Million)
Table 83. South America Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2022) & (USD Million)
Table 84. South America Antibody Drug Conjugates (ADCs) Revenue by Type (2023-2028) & (USD Million)
Table 85. South America Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2022) & (USD Million)
Table 86. South America Antibody Drug Conjugates (ADCs) Revenue by Application (2023-2028) & (USD Million)
Table 87. South America Antibody Drug Conjugates (ADCs) Revenue by Country (2017-2022) & (USD Million)
Table 88. South America Antibody Drug Conjugates (ADCs) Revenue by Country (2023-2028) & (USD Million)
Table 89. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Type (2017-2022) & (USD Million)
Table 90. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Type (2023-2028) & (USD Million)
Table 91. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Application (2017-2022) & (USD Million)
Table 92. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Application (2023-2028) & (USD Million)
Table 93. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Country (2017-2022) & (USD Million)
Table 94. Middle East & Africa Antibody Drug Conjugates (ADCs) Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Antibody Drug Conjugates (ADCs) Picture
Figure 2. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Type in 2021
Figure 3. Seattle Genetics Technology
Figure 4. ImmunoGen Technology
Figure 5. Immunomedics Technology
Figure 6. Antibody Drug Conjugates (ADCs) Revenue Market Share by Application in 2021
Figure 7. Hospital Picture
Figure 8. Clinics Picture
Figure 9. Others Picture
Figure 10. Global Antibody Drug Conjugates (ADCs) Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 11. Global Antibody Drug Conjugates (ADCs) Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Region (2017-2028)
Figure 13. Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Region in 2021
Figure 14. North America Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Europe Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. South America Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Antibody Drug Conjugates (ADCs) Market Drivers
Figure 20. Antibody Drug Conjugates (ADCs) Market Restraints
Figure 21. Antibody Drug Conjugates (ADCs) Market Trends
Figure 22. Roche Recent Developments and Future Plans
Figure 23. Pfizer Recent Developments and Future Plans
Figure 24. Novartis Recent Developments and Future Plans
Figure 25. Genmab Recent Developments and Future Plans
Figure 26. Bayer Recent Developments and Future Plans
Figure 27. Seattle Genetics Recent Developments and Future Plans
Figure 28. Takeda Pharmaceuticals Recent Developments and Future Plans
Figure 29. AbbVie Recent Developments and Future Plans
Figure 30. AbGenomics Recent Developments and Future Plans
Figure 31. ADC Therapeutics Recent Developments and Future Plans
Figure 32. Astellas Pharma Recent Developments and Future Plans
Figure 33. Kairos Therapeutics Recent Developments and Future Plans
Figure 34. Global Antibody Drug Conjugates (ADCs) Revenue Share by Players in 2021
Figure 35. Antibody Drug Conjugates (ADCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players Antibody Drug Conjugates (ADCs) Revenue Market Share in 2021
Figure 37. Global Top 10 Players Antibody Drug Conjugates (ADCs) Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global Antibody Drug Conjugates (ADCs) Revenue Share by Type in 2021
Figure 40. Global Antibody Drug Conjugates (ADCs) Market Share Forecast by Type (2023-2028)
Figure 41. Global Antibody Drug Conjugates (ADCs) Revenue Share by Application in 2021
Figure 42. Global Antibody Drug Conjugates (ADCs) Market Share Forecast by Application (2023-2028)
Figure 43. North America Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2017-2028)
Figure 44. North America Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2017-2028)
Figure 45. North America Antibody Drug Conjugates (ADCs) Revenue Market Share by Country (2017-2028)
Figure 46. United States Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2017-2028)
Figure 50. Europe Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2017-2028)
Figure 51. Europe Antibody Drug Conjugates (ADCs) Revenue Market Share by Country (2017-2028)
Figure 52. Germany Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2017-2028)
Figure 58. Asia-Pacific Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific Antibody Drug Conjugates (ADCs) Revenue Market Share by Region (2017-2028)
Figure 60. China Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2017-2028)
Figure 67. South America Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2017-2028)
Figure 68. South America Antibody Drug Conjugates (ADCs) Revenue Market Share by Country (2017-2028)
Figure 69. Brazil Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa Antibody Drug Conjugates (ADCs) Sales Market Share by Type (2017-2028)
Figure 72. Middle East and Africa Antibody Drug Conjugates (ADCs) Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa Antibody Drug Conjugates (ADCs) Revenue Market Share by Country (2017-2028)
Figure 74. Turkey Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE Antibody Drug Conjugates (ADCs) Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
